APONTIS PHARMA AG

Latest Results (18.09.2025):

APONTIS PHARMA AG has reported its financial results for the first half of 2025, demonstrating sustained revenue growth and strategic portfolio expansion. Despite a decline in EBITDA, the company successfully integrated new products and advanced its acquisition by Zentiva AG, positioning itself for future growth within the Zentiva Group.

Revenue Growth

In the first half of 2025, APONTIS PHARMA achieved a 6.2% increase in revenue from single-pill combinations, amounting to EUR 1.1 million. Total revenue rose by 14.6%, reaching EUR 3.3 million compared to the same period last year.

Sales Performance

The second quarter of 2025 saw a 6% growth in sales of single pills, maintaining the momentum from the first quarter's 6% increase. Overall revenue for the second quarter grew by 3%, following a robust 28% rise in the first quarter.

EBITDA Decline

Consolidated EBITDA for the first half of 2025 decreased by EUR 0.6 million to EUR 1.5 million, down from EUR 2.1 million in the same period of 2024. This decline highlights challenges in maintaining profitability amidst growth efforts.

Portfolio Expansion

APONTIS PHARMA expanded its product portfolio by adding CandeInda and TelmiInda, two single-pill combinations for high blood pressure. The company aims to offer a comprehensive range of single-pill combinations, with six additional development products slated for launch from 2027 onwards.

Acquisition by Zentiva AG

A resolution was passed to transfer minority shares of APONTIS PHARMA to Zentiva AG in exchange for a cash payment of EUR 10.40 per share. This move will result in APONTIS PHARMA becoming part of the Zentiva Group and ending its stock exchange listing.

Market Performance

APONTIS PHARMA's share price showed a 7.5% increase since the beginning of 2025, closing at EUR 10.75 on June 30, 2025. The company's inclusion in the Scale All Share Index contributed to a 10% rise, reflecting positive market sentiment despite broader economic challenges.